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Abstract
Coﬁlin-1 (CFL1), a small protein of 18 kDa, has been studied as a biomarker due to its involvement in tumor cell migration
and invasion. Our aim was to evaluate CFL1 as an indicator of malignancy and aggressiveness in sputum samples. CFL1 was
analyzed by ELISA immunoassay in the sputum of 73 lung cancer patients, 13 cancer-free patients, and 6 healthy volunteers.
Statistical analyses included ANOVA, ROC curves, Spearman correlation, and logistic regression. Sputum CFL1 levels were
increased in cancer patients compared to cancer-free patients and volunteers (Po0.05). High expression of sputum CFL1 was
correlated to T4 stage (P=0.01) and N stage (P=0.03), tobacco history (P=0.01), and squamous cell carcinoma histologic type
(P=0.04). The accuracy of sputum CFL1 in discriminating cancer patients from cancer-free patients and healthy volunteers were
0.78 and 0.69, respectively. CFL1 at a cut-off value of 415.25 pg/mL showed sensitivity/speciﬁcity of 0.80/0.70 in differentiating
between healthy volunteers and cancer patients. Sputum CFL1 was also able to identify cancer-free patients from patients
with lung cancer. The AUC was 0.70 and, at a cut-off point X662.63 pg/mL, we obtained 60% sensitivity and 54% speciﬁcity.
Logistic regression analysis controlled for tobacco history, histologic types, and N stage showed that cancer cell-associated
CFL1 was an independent predictor of death. Smoker patients with squamous cell carcinoma, lymph node metastasis and
sputum CFL141.475 pg/mL showed augmented chance of death, suggesting lung cancer aggressiveness. CFL1 presented
diagnostic value in detecting lung cancer and was associated to tumor aggressiveness.
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Introduction
Lung cancer (LC) is the leading cause of tumor death
worldwide, and an effective test for its early detection has
been an elusive goal for decades. Previous randomized
screening trials assessing combinations of chest radio-
graphy, sputum cytology, and low-dose helical computed
tomography were inconclusive in showing a mortality
beneﬁt from screening (1–3). However, the use of this
screening strategy has reduced lung cancer-speciﬁc
mortality by 20% (4); the majority of patients died once
metastasis occurred. This may account for deﬁciencies
in accurate diagnosis and risk stratiﬁcation. Therefore,
the identiﬁcation and validation of novel biomarkers for LC
should be considered a priority (5).
In several types of cancer, intracellular and extra-
cellular proteins have shown to be potential diagnostic
markers present in blood and secretions, such as saliva,
sputum, and urine (6,7). Coﬁlin-1 (CFL1) is an actin-
binding protein that is essential for the depolymerization
of actin ﬁlaments (8). By inducing CFL1 phosphorylation,
Rho abolishes the actin-binding activity of CFL1, thereby
enhancing the polymerization of actin ﬁlaments. LIM
kinase (LIMK) can regulate actin dynamics through the
phosphorylation of CFL1 (9). Thus, Rho regulates CFL1
via LIMK, and this signal transduction pathway modulates
actin assembly in many cell types in response to various
extracellular stimuli, playing a key role in cell migra-
tion and cytokinesis (10). CFL1 has been reported to be
directly associated to invasion, metastasis, and chemore-
sistance of various human malignant solid tumors (11–14).
Furthermore, it has also been found to be a good tumor
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biomarker present in the plasma of patients with lung
cancer at advanced stages (15). However, no previous
studies have considered sputum CFL1 expression as
a diagnostic or prognostic marker in LC. The sputum
expression of CFL1 and its clinical implication in LC was
investigated in the present study.
Material and Methods
Patients
This research was carried out in accordance with
the Declaration of Helsinki and the study was approved
by Universidade de São Paulo Ethics Committee (#256/
10). Written informed consent was obtained from all
patients.
A cohort of 73 consecutive patients with lung cancer at
the Instituto do Cancer and Hospital do Cancer, Barretos,
SP, Brazil were included. Moreover, 13 patients classiﬁed
as cancer-free and 6 as healthy volunteers were included.
The cancer-free patients (9 men and 4 women) had
a median age of 62 years (range 32–78 years) and
presented symptoms of chronic bronchitis. From these
patients, 4 were smokers, 2 were non-smokers, 6 were
former smokers, and we did not have this information for
one patient. Former smokers were deﬁned as patients
who had left the tobacco habit for more than 1 year.
All 6 healthy volunteers (one man and ﬁve women) were
selected during the investigation for non-pulmonary diseases.
The median age was 73.5 years (range 65–78 years) and
2 patients were smokers.
Sputum samples
Spontaneous sputum was collected from LC patients
just prior to bronchoscopy, and sputum induction through
3 inhalations of 4% hypertonic saline (7 min each) was
used for cancer-free patients and healthy volunteers.
The sputum samples were stored on ice until processing.
To minimize salivary contamination, the samples were
visually examined in sterile Petri dishes and then stored
at –80°C until the analyses.
Detection of CFL1 in sputum
The levels of CFL1 were determined by a ‘sandwich’
ELISA test according to the manufacturer’s guidelines
(USCN Business Co. Ltd, USA). Sputum samples and
control standards were added to pre-sensitized plates with
anti-CFL1 antibody and incubated at room temperature
(RT) for 2 h. After incubation, a biotinylated conjugate
antibody was added and incubated at RT for 2 h. Then,
streptavidin HRP was added to plates and incubated at
RT for 30 min. The plates were washed with Wash Buffer
(PBS + Tween 20) 6 times. Revelation was done by
adding H2O2 with tetramethyl benzidine and the reaction
was blocked with 30% H2SO4. The reading was taken
in an ELISA reader (Power Wave Bio-Tek, USA) using a
450 nm ﬁlter. The minimum detectable level for CFL1 was
78.1 pg/mL. The assays were run in triplicate and the
results are reported as means±SD.
Statistical analysis
Statistical analyses were performed using SPSS
Inc. version 18 (USA). Descriptive analysis of quantitative
and qualitative data was done, and normal distribu-
tion veriﬁed with Kolmogorov-Smirnov test. The compar-
ison among histological types, demographics data, and
sputum CFL1 was done with Fisher’s exact test and
chi-squared test. ROC curves were used to evaluate
the accuracy of sputum CFL1 in the diagnosis of LC,
measured by the area under the curve (AUC). The cut-off
values depicted in ROC curves represent the point at
which the sensitivity and speciﬁcity simultaneously demon-
strate higher values (16). Logistic regression was used
to evaluate the risk of death for patients with lung cancer
based on the levels of CFL1. The Bonferroni method
was also used, if necessary. A P value of p0.05 was
considered to be signiﬁcant.
Results
Clinical and pathological characteristics including
age, gender, tumor stage, histological types, and tobacco
history are reported in Table 1. Ten patients died and
63 were alive until the end of the study.
The results of CFL1 stratiﬁed by the presence or
absence of LC are shown in Table 2. A signiﬁcant increase
of sputum CFL1 was observed in patients with lung cancer
(1475.83±145.35 pg/mL) compared to cancer-free patients
(662.63±5.74 pg/mL) and healthy volunteers (415.25±
3.68 pg/mL) (P=0.01) (Figure 1). ROC curves constructed
to demonstrate the accuracy of sputum CFL1 in discrimi-
nating cancer patients from cancer-free patients and healthy
volunteers were 0.78 and 0.69, respectively. At a cut-off
point of CFL1X415.25 pg/mL, the sensitivity and speci-
ﬁcity was 70 and 80% (Figure 2A). Sputum CFL1 was
also able to distinguish cancer-free patients from patients
with LC. With the AUC at 0.70 and the cut-off point
X662.63 pg/mL, we obtained 60% sensitivity and 54%
speciﬁcity (Figure 2B). In a clinical setting, with a 425
pack-year smoking history, CFL1 could be useful to predict
lymph node metastasis with an AUC of 0.96 (Figure 3).
The univariate analysis showed that a high concentra-
tion of sputum CFL1 is correlated to T4 stage (P=0.01),
presence of lymph node metastases (P=0.03), tobacco
history (P=0.01), and squamous cell carcinoma subtype
(P=0.04). Therefore, we constructed logistic regression
models with these variables to determine the risk of
distant metastases; the best model is shown in Table 3.
This model, controlled for smoking history, histological
subtypes, and N staging, showed that sputum CFL1 of
patients with LC is an independent predictive factor of
death [OR=5.77 (0.78–42.74)] (–2Log likelihood d=41.32,
Po0.01). On the other hand, squamous cell subtype
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with sputum CFL141.475 pg/mL showed an augmented
chance of death, reinforcing the role of CFL1 as a potential
biomarker of aggressiveness in LC.
Discussion
We demonstrated that patients with LC present signif-
icant increases in CFL1 levels in sputum, emerging there-
fore as a potential biomarker for LC diagnosis. In addition,
we found that cancer patients contain higher concentra-
tions of sputum CFL1 compared to cancer-free patients
and healthy volunteers. This ﬁnding is relevant since it
represents an unprecedented biomarker to be used for
LC screening, which does not require invasive proce-
dures. Although induced sputum collection is a slightly
less comfortable method for the patient than spontaneous
sputum collection, adverse effects are minimal, and usually
associated with bronchoconstriction. The present study
did not show any adverse effects during or after the
procedure.
The relevance of sputum CFL1 remained high even
when the concentration was compared between cancer
patients and healthy volunteers, cancer patients and cancer-
free patients, and cancer-free patients and healthy volun-
teers. As far as we know, such molecules have never been
assayed in the sputum; however, our results corroborated
those by Zheng et al. (15).
We also found an association between the concen-
tration of CFL1 and squamous cell carcinoma subtype.
In a previous study, our group showed that hyaluronic
acid, a GAG not sulfated component of the extracellular
matrix, was increased in sputum of patients with LC (7)
particularly in squamous cell carcinoma, and probably
associated to the more central location of this subtype
of cancer in the respiratory tree. In addition, other tests
performed in sputum, as cytology, are more useful in
cases of squamous cell carcinoma, since its more central
location favors a higher production of sputum (17).
In our study, a concentration of CFL1 above 468 pg/mL
demonstrated sensitivity and speciﬁcity of 80 and 70%,
respectively, in discriminating patients with lung cancer
from healthy volunteers. The disadvantage of this cut-off
point is that around 30% of patients with cancer can have
a false negative diagnosis making the test inconclusive,
and requiring conventional methods for diagnostic elucida-
tion, such as bronchoscopy. However, the results presented
in this study are highly relevant, since the search for diag-
nostic markers related to LC has been the subject of much
research in recent decades. According to Gadgeel (17),
Table 1. Clinical and pathological features of
patients with lung cancer.
Patients 73 patients
Age (years) 60 (37–89)a
Gender (M/F) 49/24
T stage
1 11
2 19
3 14
4 29
N stage
0 10
1 14
2 22
3 27
M stage
0 33
1 40
Stage
IB 10
IIA 2
IIB 1
IIIA 5
IIIB 16
IV 39
Histologic types
SCC 30
AD 33
LCC 5
SCLC 5
Tobacco history
Yes 18
No 12
Former 43
Follow-up (months) 27 (0–70)a
Data are reported as median (range)a and num-
bers. SCC: squamous cell carcinoma; AD: adeno-
carcinoma; LCC: large cell carcinoma; SCLC:
small cell lung carcinoma.
Table 2. Descriptive analysis of coﬁlin-1 in the sputum of cancer patients, cancer-free patients, and volunteers.
Coﬁlin-1 n Mean
(pg/mL)
Standard
deviation
Standard
error
95% Conﬁdence Interval for mean Minimum Maximum
Lower bound Upper bound
Volunteers 6 415.25 578.65 236.23 –192.00 1022.50 78.10 1554.80
Cancer-free 13 662.63 564.01 156.43 321.79 1003.46 78.10 1521.70
Cancer 73 1475.83 1241.87 145.35 1186.07 1765.58 78.10 4239.40
Total 92 1291.75 1189.52 124.01 1045.41 1538.09 78.10 4239.40
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various study groups have been trying to ﬁnd a serum
or sputum biomarker for lung cancer detection, but to
date, none of these markers showed broad application
in clinical practice. Most of the conventional techniques
are invasive and cause great discomfort and anxiety,
or even bring painful side effects to the patients (17,18).
Therefore, adjuvant screening tests would be highly bene-
ﬁcial for patients with a medical history of or high risk for
developing lung cancer.
The levels of CFL1 in sputum seem to present
an impact on the natural history of patients with lung
cancer. Interestingly, we showed that high a concentration
of CFL1 correlated to T4 stage, lymph node metastases,
and tobacco history. In fact, by analyzing the logistic re-
gression controlled for tobacco history, histological types,
and staging, we observed that the concentration of sputum
CFL1 was an independent predictor of risk of lymph node
metastases in patients with lung cancer. These results
indicate that the concentration of this protein in sputum is
related to tumor progression, probably as a consequence
Figure 1. Levels of sputum coﬁlin-1 in healthy volunteers, cancer-
free and lung cancer patients. Data are reported as means±SD.
P=0.01 for between groups comparisons (chi-squared test).
Figure 3. Analysis of coﬁlin-1 levels in patients with 425 pack-year smoking frequency. A, ROC curve for the discrimination between
normal controls and patients with lung cancer. B, Coﬁlin-1 in patients with metastasis. C, ROC curve for the discrimination between
presence or absence of metastasis based on coﬁlin-1 levels. In B, data are reported as means±SD. *Po0.05 compared to control;
**Po0.05 compared to no metastasis (chi-squared test).
Figure 2. ROC curves representing the diagnostic ability of coﬁlin-1 level in sputum (A) to distinguish cancer patients from healthy
people (AUC=0.78) and (B) to differentiate cancer-free patients from cancer patients at high risk (AUC= 0.69).
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of modiﬁcations in the extracellular matrix (ECM) earlier in
the carcinogenesis process, i.e., at the stage of neoplastic
transformations. According to Wistuba et al. (19), this is a
phase of ECM tissue remodeling, which can affect sputum
composition and production of its components. As men-
tioned earlier, the interaction between tumor cells and the
neoplastic microenvironment, represented by the ECM,
inﬂuences the invasive and metastatic properties of tumors.
Despite the difference in CFL1 behavior among the
studied groups, some limitations of the study should be
highlighted. First, despite the small number of volunteers
included in the control group, we have to consider the
difﬁculty of recruiting healthy people with the same age of
patients with lung cancer for collecting induced sputum
samples. Because of this difﬁculty, there is a difference in
the number of patient cases and the number of normal
cases. However, the considerable increase in CFL1 in the
sputum of patients with lung cancer suggest that changes
have already occurred at the beginning of carcinogenesis,
giving this protein a promising role as a lung cancer
biomarker.
Another limitation of the study is that samples were
stored at –80°C, hindering a cytological study of sputum,
which would certainly add sensitivity to the diagnosis of
lung cancer.
In addition, it should be considered that at the time of
sputum collection, some patients were recently diagnosed
with lung cancer, thus had a short period of follow-up to be
evaluated.
Considering the results presented here, CFL1 in sputum
could be considered a promising screening test for applica-
tion in clinical practice, since it is an alternative tool to
detect the disease by means of a non-invasive procedure.
However, for its application in the diagnostic routine,
a larger number of cancer cases should be studied.
Nevertheless, the results observed and discussed here
indicate an unquestionable role of this protein in the
natural history of lung cancer.
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